Conditions: Alzheimer's Disease
Keywords: Randomized Safety Study Open Label
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 52
Healthy volunteers: no

Brief summary:
This is a study to evaluate the safety and tolerability of multiple doses of AAB-003 (PF-05236812) in patients with mild to moderate Alzheimer's Disease. Patients who complete study B2601001 may participate in this trial and receive AAB-003 (PF-05236812). Each patient's participation will last approximately 52 weeks.

Detailed description:

Arms:
arm 1: None arm 2: None arm 3: None arm 4: None arm 5: None

Interventions: intervention 1: AAB-003 (PF-05236812) intervention 2: AAB-003 (PF-05236812) intervention 3: AAB-003 (PF-05236812) intervention 4: AAB-003 (PF-05236812) intervention 5: AAB-003 (PF-05236812)
Intervention descriptions: intervention 1: 0.5 mg/kg AAB-003, IV intervention 2: 1 mg/kg AAB-003, IV intervention 3: 2 mg/kg AAB-003, IV intervention 4: 4 mg/kg AAB-003, IV intervention 5: 8 mg/kg AAB-003, IV

Protocol document: